Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

October 03, 2022

Study establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.

June 23, 2022

Eunice Wang, MD, discusses the long-term results of a phase 2 trial investigating crenolanib plus chemotherapy in adult patients with newly diagnosed FLT3-mutant acute myeloid leukemia.

May 09, 2022

Igor Puzanov, MD, MSCI, FACP, discusses the adverse effects associated with immunotherapy and how to manage them.

April 25, 2022

Ciltacabtagene autoleucel generated deep responses and demonstrated manageable safety in patients with progressive multiple myeloma who were refractory to lenalidomide.

April 10, 2022

Sotorasib demonstrated an overall survival rate of 32.5% at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer, according to longer follow-up data from the phase 1/2 CodeBreaK 100 trial.

February 11, 2022

The utilization of monoclonal antibodies such as nivolumab and Ipilimumab have become vital in shifting the treatment paradigm in gastroesophageal and gastrointestinal cancers.

February 10, 2022

Dhyan Chandra, PhD, discusses recent findings relating to low levels of cytochrome C in Black men with prostate cancer, plus plans for future research on this topic.

February 09, 2022

Anna Woloszynska, PhD, discusses the role of community outreach in addressing disparities in prostate cancer.

January 28, 2022

Dhyan Chandra, PhD, discusses the need for resources to evaluate racial disparities in prostate cancer.

January 26, 2022

Neoadjuvant chemosensitivity was associated with an improvement in overall survival following adjuvant chemotherapy in patients with resectable gastric cancer, according to findings from a cohort study that were published in JAMA Network Open.

January 26, 2022

Anna Woloszynska, PhD, discusses continued research efforts investigating racial disparities in prostate cancer.

January 25, 2022

The combination of tivozanib and durvalumab showcased early efficacy with a manageable safety profile in patients with previously untreated advanced hepatocellular carcinoma.

January 25, 2022

Nathaniel Ivanick, MD, FCCP, explains advancements in the use of robotic navigational bronchoscopy for the diagnosis of early-stage lung cancer.

January 24, 2022

Dhyan Chandra, PhD, discusses evaluating biological differences between African American and Caucasian men with prostate cancer.

January 19, 2022

Dhyan Chandra, PhD, discusses the potential to assess mitochondrial function to inform outcomes in prostate cancer.

January 19, 2022

Anna Woloszynska, PhD, discusses the need to assess biological factors of racial disparities in prostate cancer.

January 06, 2022

New grants from the U.S. Department of Defense and American Cancer Society will fund work by two Roswell Park Comprehensive Cancer Center teams focused on understanding and eliminating prostate cancer health disparities.

November 23, 2021

Nathaniel Ivanick, MD, FCCP, discusses the evolution of interventional pulmonology, the benefits of robotic navigational bronchoscopy and other novel technologies in the field, and ongoing research that could further push the paradigm forward.

November 11, 2021

Nathaniel Ivanick, MD, FCCP, discusses the role of interventional pulmonologists in advanced diagnostics in lung cancer.

November 10, 2021

Following a national search, Roswell Park Comprehensive Cancer Center has promoted Emese Zsiros, MD, PhD, FACOG, to lead its Department of Gynecologic Oncology.